Hyperlipidemia News and Research

RSS

Hyperlipidemia, hyperlipoproteinemia or dyslipidemia is the presence of raised or abnormal levels of lipids and/or lipoproteins in the blood. Lipids (fatty molecules) are transported in a protein capsule, and the density of the lipids and type of protein determines the fate of the particle and its influence on metabolism.

Novel approach to reduce 'bad' lipids in blood circulation

Xian-Cheng Jiang, PhD, professor of cell biology at SUNY Downstate Medical Center, has led a study identifying a new approach for lowering "bad" lipids in blood circulation, a critical means to combat devastating cardiovascular diseases such as atherosclerosis. The research was published in the online edition of Gastroenterology.

3 Sep 2015

Potential molecular link identified between excess fat in the blood and blood vessel recovery in ischemia

The buildup of fat in the blood makes a bad situation worse - it not only raises a person's risk for heart attack or stroke but also impairs the growth of new blood vessels. How excess fat in the blood - a condition known as hyperlipidemia - blocks vessel growth was unclear, but new work by researchers at Temple University School of Medicine shows that a molecule known as caspase-1 plays a central role and that preventing its activity could be the key to building new blood vessels and restoring blood supply to oxygen-starved tissues.

10 Jul 2015

Researchers analyze cardiometabolic benefits of exercise

Everyone knows that exercise generally helps the cardiovascular system, but much remains unknown about how the benefits arise, and what to expect in different people who exercise to improve their health. To gain a more precise understanding of how exercise improves health and whom it helps most, researchers analyzed the results of 160 randomized clinical trials with nearly 7,500 participants.

3 Jul 2015

DCRI announces new study to better understand lipid management

At a time when lipid management in the United States is undergoing transition in response to new guideline recommendations and expanding lipid-lowering therapy options, the Duke Clinical Research Institute (DCRI) today announced a new study to better understand contemporary lipid management as well as the beliefs and attitudes of patient and providers regarding cholesterol, cardiovascular risk assessment, and options for lipid treatments.

17 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death.

28 Apr 2015

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).

23 Mar 2015

Patients with symptoms of mental illness less likely to receive advice from health care providers

More than half of patients with symptoms of mental illness - and nearly one-third of those who also had diabetes - said their health care providers had never told them to exercise or reduce their intake of dietary fat, according to a new study published in Diabetes Educator.

25 Feb 2015

Physicians in subspecialties report increased satisfaction with concierge medicine model

Attracted to the opportunity to provide concierge medicine's hallmark model of personalized care, physicians in subspecialties such as cardiology, endocrinology, pulmonology, and others are increasingly converting their practices, and reporting increased professional and personal satisfaction, according to Michael Friedlander, Principal at national healthcare consulting firm Specialdocs.

20 Jan 2015

DPS Health states that tackling Emergent-Risk cohort becomes a high priority

The Emergent-Risk population represents one of the greatest threats to population health and will overwhelm the current U.S. healthcare system if something isn't done to engage these individuals in improving their health and quality of life, warned Neal Kaufman, MD, co-founder and Chief Medical Officer of DPS Health.

13 Jan 2015

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol.

11 Nov 2014

Gastric bypass surgery provides better results than gastric banding

Gastric bypass surgery has better outcomes than gastric banding for long-term weight loss, controlling type 2 diabetes and high blood pressure, and lowering cholesterol levels, according to a new review by UT Southwestern Medical Center surgeons of nearly 30 long-term studies comparing the two types of bariatric procedures.

26 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.

28 Aug 2014

Risk factors for hospital readmissions identified in stroke patients

Hospital readmission, an important measure of quality care, costs the United States an estimated $17 billion each year. And according to the Centers for Medicare and Medicaid Services, about half of those readmissions could be avoided.

11 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Sanford-Burnham, Daiichi enter into comprehensive alliance to develop first-in-class therapeutics

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases.

22 May 2014

Free access to fitness center is not well utilized by low income community

Eliminating financial barriers to a fitness center as well as providing physician support, a pleasant environment and trained fitness staff did not result in widespread membership activation or consistent attendance among low income, multi-ethnic women with chronic disease risk factors or diagnoses according to a new study from Boston University School of Medicine.

15 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014